ES2539917T3 - GLP-2 para su uso en el tratamiento de la atrofia muscular - Google Patents
GLP-2 para su uso en el tratamiento de la atrofia muscular Download PDFInfo
- Publication number
- ES2539917T3 ES2539917T3 ES10762684.8T ES10762684T ES2539917T3 ES 2539917 T3 ES2539917 T3 ES 2539917T3 ES 10762684 T ES10762684 T ES 10762684T ES 2539917 T3 ES2539917 T3 ES 2539917T3
- Authority
- ES
- Spain
- Prior art keywords
- glp
- treatment
- rats
- activities
- jejunum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 title abstract description 22
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 title abstract description 22
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 title abstract description 22
- 201000000585 muscular atrophy Diseases 0.000 title 1
- 208000026214 Skeletal muscle atrophy Diseases 0.000 abstract description 2
- 230000025185 skeletal muscle atrophy Effects 0.000 abstract description 2
- 101710173664 Glucagon-2 Proteins 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 17
- 230000000694 effects Effects 0.000 description 14
- 235000003642 hunger Nutrition 0.000 description 14
- 210000001630 jejunum Anatomy 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 210000003405 ileum Anatomy 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 7
- 210000000813 small intestine Anatomy 0.000 description 5
- 102000004225 Cathepsin B Human genes 0.000 description 4
- 108090000712 Cathepsin B Proteins 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000037351 starvation Effects 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 230000002132 lysosomal effect Effects 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 210000002303 tibia Anatomy 0.000 description 3
- 108090000317 Chymotrypsin Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 2
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 2
- 229960002376 chymotrypsin Drugs 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 102100037469 Protein DEPP1 Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000037012 chymotrypsin-like activity Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000001810 trypsinlike Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09172398A EP2311486A1 (en) | 2009-10-07 | 2009-10-07 | GLP-2 for use in intestine and muscle recovery |
| EP09172398 | 2009-10-07 | ||
| PCT/EP2010/065021 WO2011042501A2 (en) | 2009-10-07 | 2010-10-07 | The intestine and muscle recovery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2539917T3 true ES2539917T3 (es) | 2015-07-07 |
Family
ID=41611235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10762684.8T Active ES2539917T3 (es) | 2009-10-07 | 2010-10-07 | GLP-2 para su uso en el tratamiento de la atrofia muscular |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20120270786A1 (enExample) |
| EP (2) | EP2311486A1 (enExample) |
| JP (1) | JP5801814B2 (enExample) |
| CN (1) | CN102711803B (enExample) |
| AU (1) | AU2010305420B2 (enExample) |
| BR (1) | BR112012009380A2 (enExample) |
| CA (1) | CA2776964C (enExample) |
| DK (1) | DK2485756T3 (enExample) |
| ES (1) | ES2539917T3 (enExample) |
| IN (1) | IN2012DN03187A (enExample) |
| WO (1) | WO2011042501A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160051814A1 (en) * | 2013-04-15 | 2016-02-25 | Nestec S.A. | Use of whey protein in combination with electrical muscle stimulation |
| JP6325215B2 (ja) * | 2013-08-29 | 2018-05-16 | テルモ株式会社 | 栄養補給用冷菓 |
| ES2960218T3 (es) * | 2014-10-14 | 2024-03-01 | Nestle Sa | Mejora en la funcionalidad del músculo de hombres ancianos |
| KR101661332B1 (ko) | 2015-05-28 | 2016-09-29 | (의료)길의료재단 | 글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물 |
| US10993993B2 (en) | 2015-05-28 | 2021-05-04 | Immunoforge Co., Ltd. | Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist |
| KR102119188B1 (ko) * | 2018-11-13 | 2020-06-08 | 이뮤노포지 주식회사 | 글루카곤 유사 펩타이드-1(glp-1), glp-1 유래 펩타이드, 또는 glp-1 분해 억제제를 포함하는 근감소증 또는 근위축증 치료용 약학 조성물 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5661123A (en) * | 1995-01-17 | 1997-08-26 | Nestec, Ltd. | Enteral composition for malabsorbing patients |
| US5834428A (en) * | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| US5990077A (en) * | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| US6852690B1 (en) * | 1995-08-22 | 2005-02-08 | Amylin Pharmaceuticals, Inc. | Method and composition for enhanced parenteral nutrition |
| CN1268640C (zh) * | 1996-04-12 | 2006-08-09 | 1149336安大略公司 | 胰高血糖素样肽－2的类似物 |
| CA2223198A1 (en) * | 1997-01-14 | 1998-07-14 | Societe Des Produits Nestle S.A. | Composition and method for treatment of inflammatory conditions of the gastro-intestinal tract |
| CA2236519C (en) * | 1997-05-02 | 2011-09-13 | 1149336 Ontario Inc. | Methods of enhancing functioning of the large intestine |
| EP1090636A1 (en) * | 1999-09-13 | 2001-04-11 | Société des Produits Nestlé S.A. | High lipid diet |
| ATE396738T1 (de) * | 2000-09-18 | 2008-06-15 | Sanos Bioscience As | Verwendung von glp-2-peptiden |
| US7186683B2 (en) * | 2000-09-18 | 2007-03-06 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
| WO2002066511A2 (en) * | 2001-02-16 | 2002-08-29 | Conjuchem Inc. | Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders |
| PL376223A1 (en) * | 2002-10-14 | 2005-12-27 | Novo Nordisk As | Glucagon - like peptide - 2 variants |
| US20040115708A1 (en) * | 2002-10-28 | 2004-06-17 | Ardies C. Murray | Method of screening agents for the treatment and prevention of cancer and cachexia and the new use of specific agents for the treatment and prevention of cancer and cachexia |
| JP4699374B2 (ja) * | 2003-05-15 | 2011-06-08 | トラスティーズ オブ タフツ カレッジ | 安定なペプチド及びポリペプチドアナログ治療剤 |
| JP5788631B2 (ja) * | 2005-04-06 | 2015-10-07 | ネステク ソシエテ アノニム | グルコース制御およびインスリン作用を栄養的に改善するための方法および組成物 |
| CN101365350A (zh) * | 2006-01-09 | 2009-02-11 | 雀巢技术公司 | 应激患者的治疗 |
| NZ576260A (en) * | 2006-11-08 | 2012-04-27 | Zealand Pharma As | GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES comprising one of more substitutions as compared to h[Gly2]GLP-2 |
-
2009
- 2009-10-07 EP EP09172398A patent/EP2311486A1/en not_active Withdrawn
-
2010
- 2010-10-07 IN IN3187DEN2012 patent/IN2012DN03187A/en unknown
- 2010-10-07 WO PCT/EP2010/065021 patent/WO2011042501A2/en not_active Ceased
- 2010-10-07 JP JP2012532595A patent/JP5801814B2/ja active Active
- 2010-10-07 US US13/500,784 patent/US20120270786A1/en not_active Abandoned
- 2010-10-07 EP EP10762684.8A patent/EP2485756B1/en active Active
- 2010-10-07 DK DK10762684.8T patent/DK2485756T3/en active
- 2010-10-07 CN CN201080055259.6A patent/CN102711803B/zh active Active
- 2010-10-07 CA CA2776964A patent/CA2776964C/en active Active
- 2010-10-07 BR BR112012009380-0A patent/BR112012009380A2/pt not_active Application Discontinuation
- 2010-10-07 AU AU2010305420A patent/AU2010305420B2/en active Active
- 2010-10-07 ES ES10762684.8T patent/ES2539917T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010305420A1 (en) | 2012-05-10 |
| HK1173949A1 (en) | 2013-05-31 |
| EP2485756A2 (en) | 2012-08-15 |
| BR112012009380A2 (pt) | 2021-06-22 |
| WO2011042501A3 (en) | 2011-06-03 |
| JP2013507341A (ja) | 2013-03-04 |
| AU2010305420B2 (en) | 2015-03-19 |
| US20120270786A1 (en) | 2012-10-25 |
| CN102711803B (zh) | 2017-02-22 |
| IN2012DN03187A (enExample) | 2015-09-25 |
| CN102711803A (zh) | 2012-10-03 |
| EP2485756B1 (en) | 2015-05-20 |
| EP2311486A1 (en) | 2011-04-20 |
| CA2776964C (en) | 2019-03-05 |
| WO2011042501A2 (en) | 2011-04-14 |
| CA2776964A1 (en) | 2011-04-14 |
| DK2485756T3 (en) | 2015-06-08 |
| JP5801814B2 (ja) | 2015-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2539917T3 (es) | GLP-2 para su uso en el tratamiento de la atrofia muscular | |
| RU2012125827A (ru) | Применение аналога тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции | |
| PE20050123A1 (es) | Derivados de heteroarilamida benzocondensada de tienopiridinas y composiciones farmaceuticas que los incluyen | |
| NZ544645A (en) | Use of calcitonin in osteoarthritis | |
| BRPI0412761A (pt) | inibidores de serino proteases, particularmente a protease ns3-ns4a do vhc | |
| TW200510391A (en) | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | |
| EA201270069A1 (ru) | Быстрорастворимая оральная пленочная лекарственная форма, содержащая стевиозиды в качестве агента, маскирующего неприятный вкус | |
| ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
| PE20040157A1 (es) | Progestinas no esteroides | |
| AR035927A1 (es) | Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr | |
| WO2002078627A3 (en) | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity | |
| CY1114448T1 (el) | Φαρμακευτικες συνθεσεις και χρηση αυτων στην αγωγη της γυναικειας σεξουαλικης δυσλειτουργιας | |
| MX2010005629A (es) | Preparacion farmaceutica para tratamiento de hiperplasia prostatica benigna. | |
| AR020803A1 (es) | Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento | |
| RU2013150659A (ru) | Пероральное введение кальцитонина | |
| NZ595376A (en) | Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration | |
| AR047776A1 (es) | Composiciones farmaceuticas glp - 1 | |
| AR044200A1 (es) | Composicion de fondaparinux sodico de alta pureza ,un procedimiento de preparacion de esta composicion y composiciones farmaceuticas que la contienen como principio activo | |
| PH12012500827A1 (en) | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin | |
| BR0317095A (pt) | Uso de uma combinação contendo um inibidor da transcriptase reversa sem ser de nucleosìdeo (nnrti) com um inibidor citocromo p450, tal como inibidores da protease | |
| HUP0301828A2 (hu) | Apomorfin alkalmazása nemi mżködészavar meghatározott apomorfin-plazmakoncentrációval történż kezelésre szolgáló készítmények elżállítására | |
| PE20061314A1 (es) | Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo | |
| MXPA05008403A (es) | Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion. | |
| Mochizuki et al. | Therapeutic efficacy of pycnogenol in experimental inflammatory bowel diseases | |
| UY26595A1 (es) | Formulaciones de entecavir de dosis bajas y uso |